KLAVA
Created in 2021
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
1,747Activities
Technologies
Entity types
Location
92100 Boulogne-Billancourt, France
Boulogne-Billancourt
France
Employees
Scale: 2-10
Estimated: 15
SIREN
893532044Engaged catalyst
15
0 0Added in Motherbase
1 year, 2 months ago
Value proposition
Together, let's build healthy technology.
KLAVA was founded with a clear mission: to improve access to evidence-based care for individuals with addictive disorders. Stigma and discrimination surrounding these conditions frequently delay access to treatment, leading to gaps in medical care and suboptimal outcomes.
In collaboration with the Addiction Medicine Department at AP-HP Paul Brousse, the leading addiction research center in Europe, KLAVA is dedicated to advancing equitable access to high-quality care for patients affected by substance use disorders.
KLAVA has concentrated its research efforts on tobacco dependence by developing Quitoxil®, a digital therapeutic accessible via smartphone, designed to assist individuals in reducing or stopping tobacco use. The therapeutic program incorporates clinically validated cognitive and behavioral therapies, providing patients with tools to identify the underlying mechanisms driving their addiction and adopt evidence-based strategies to facilitate cessation.
In 2024, Quitoxil® became the first French digital therapeutic for addiction to be distributed in community pharmacies. With thousands of downloads, KLAVA is establishing itself as a pioneer in the field of digital therapeutics for addiction medicine and as a European leader in this domain. Over the next 12 months, the company intends to expand its scope to address other addiction-related conditions, including sugar addiction.
Digital therapeutics, addiction, tobacco addiction, sugar addiction, and medical deviceOriginal language
Together, let's build healthy technology.
KLAVA was founded with a clear mission: to improve access to evidence-based care for individuals with addictive disorders. Stigma and discrimination surrounding these conditions frequently delay access to treatment, leading to gaps in medical care and suboptimal outcomes.
In collaboration with the Addiction Medicine Department at AP-HP Paul Brousse, the leading addiction research center in Europe, KLAVA is dedicated to advancing equitable access to high-quality care for patients affected by substance use disorders.
KLAVA has concentrated its research efforts on tobacco dependence by developing Quitoxil®, a digital therapeutic accessible via smartphone, designed to assist individuals in reducing or stopping tobacco use. The therapeutic program incorporates clinically validated cognitive and behavioral therapies, providing patients with tools to identify the underlying mechanisms driving their addiction and adopt evidence-based strategies to facilitate cessation.
In 2024, Quitoxil® became the first French digital therapeutic for addiction to be distributed in community pharmacies. With thousands of downloads, KLAVA is establishing itself as a pioneer in the field of digital therapeutics for addiction medicine and as a European leader in this domain. Over the next 12 months, the company intends to expand its scope to address other addiction-related conditions, including sugar addiction.
KLAVA INNOVATION
https://klava-innovation.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 La French Tech Côte d'Azur French Tech, IT Services and IT Consulting | La French Tech Côte d'Azur French Tech, IT Services and IT Consulting | Other 17 Feb 2025 | | |
 Métropole Nice Côte d'Azur Government Administration, French metropolis | Métropole Nice Côte d'Azur Government Administration, French metropolis | Other 14 Feb 2025 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 10 Nov 2024 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 25 Sep 2024 | | |
 La Banque Postale Bank, Banking | La Banque Postale Bank, Banking | Other 25 Sep 2024 | | |
 GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Other 25 Sep 2024 | | |
 Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Other 25 Sep 2024 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 25 Sep 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 1 Oct 2024 | | |
 Invest in Côte d'Azur - Team Nice Côte d'Azur Startup accelerator & VC, International Trade and Development | Invest in Côte d'Azur - Team Nice Côte d'Azur Startup accelerator & VC, International Trade and Development | Other 21 Jan 2025 | | |